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Abstract
Background: We wished to develop alternate production strategies to generate antibodies against traditionally problematic
antigens. As a model we chose butyrylcholinesterase (BChE), involved in termination of cholinergic signaling, and widely
considered as a poor immunogen.
Methodology/Principal Findings: Jettisoning traditional laborious in silico searching methods to define putative epitopes,
we simply immunized available BChE knock-out mice with full-length recombinant BChE protein (having been produced for
crystallographic analysis). Immunization with BChE, in practically any form (recombinant human or mouse BChE, BChE
purified from human serum, native or denatured), resulted in strong immune responses. Native BChE produced antibodies
that favored ELISA and immunostaining detection. Denatured and reduced BChE were more selective for antibodies specific
in Western blots. Two especially sensitive monoclonal antibodies were found capable of detecting 0.25 ng of BChE within
one min by ELISA. One is specific for human BChE; the other cross-reacts with mouse and rat BChE. Immunization of wild-
type mice served as negative controls.
Conclusions/Significance: We examined a simple, fast, and highly efficient strategy to produce antibodies by mining two
expanding databases: namely those of knock-out mice and 3D crystallographic protein-structure analysis. We conclude that
the immunization of knock-out mice should be a strategy of choice for antibody production.
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Introduction
Monoclonal and polyclonal antibodies are essential tools for
biological research. A necessity for structure function studies of
proteins both in vivo and in vitro, antibodies with new and varied
properties are constantly in demand. Complications in antibody
generation, however, often leave this tool void in the repertoire of
those available for the study of many proteins. A commonly held
explanation for the failure of antibody production following
immunization is a limited antigenic response due to high
conservation between the antigen and the endogenous proteins
of the immunized host. To circumvent this problem an antigen is
designed in silico that carries one specific epitope. This strategy
involves several steps, including: 1) selection of a primary sequence
that is divergent between the different species (immunizing antigen
and host to be immunized); 2) evaluation of sequence accessibility
in the 3D structure, if available (i.e., presence on the surface of the
protein); 3) peptide synthesis and attempts to obtain folding into
the native 3D structure and 4) immunization of the distant species.
This commonly used strategy can be efficient, despite its
complexity and time-consumption. Often, however, non-selectivity
(or cross-reactivity) of the antibody is encountered and this
problem is usually only uncovered when the antibody is used in a
background in which the gene encoding the protein of original
interest has been knocked-out or knocked-down [1,2]. Presence of
non-specific labeling or binding in this case is due to the presence
of the epitope in other proteins. In cases where the protein of
interest is studied in a species in which the deletion of the gene is
not possible, the control for cross-reactivity is more difficult.
In some gene therapy paradigms, on the other hand, unwanted
production of an antibody against a selected protein has been
described. In these cases an immune-naive host eliminates the newly
synthesized protein by standard immune responses, essentially
‘‘sabotaging’’ the gene therapy goal [3,4]. Along this line, the idea
of the immunization of ‘‘knock-out’’ mice was proposed to overcome
the problem of inter-species sequence similarity in antibody
production [5]. Indeed, this strategy has been successfully used in a
few studies but has, however, never become a common method of
choice for antibody production. Most likely this is due to the limited
variety of genetically modified animals, as well as the lack of a
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Whatever the case, here we revisit this issue and shed new light on
this simple and efficient mouse immunization strategy (figure 1).
As a test case of this strategy to obtain antibodies, we choose a
‘‘problematic’’ antigen - butyrylcholinesterase (BChE). BChE is a
well-characterized enzyme, highly abundant in serum and in
tissue, and involved in the hydrolysis of acetylcholine and
detoxification of several drugs [6]. During the 1980s, several
monoclonal antibodies against human BChE were obtained, but
due to their weak affinity they have proved to be not very useful
[7,8]. Currently there are no antibodies either polyclonal or
monoclonal that recognize mouse or rat BChE in histochemistry,
immunoprecipitation or Western blots. Explanations for this could
be that BChE is highly glycosylated and/or the high inter-species
conservation of the sequence. For our test of this method we used
mice with a complete deletion of the BChE catalytic domain [9].
These animals are without any obvious phenotypic changes. As an
immunogen, we first used sugar-diminished full-length recombi-
nant human BChE that was prepared previously to study the 3D
structure [10]. In next steps enzyme from different source was
used, recombinant mouse BChE or serum human BChE and the
antigen was differently prepared (native or denatured).
Results
Immunization with recombinant low-sugar protein
The immune response to the recombinant BChE was strong in all
immunized BChE 2/2 animals as tested in both ELISA and
immunohistochemistry of fixed COS cells expressing human BChE.
The amount of antibody produced varied from mouse to mouse and
did not depend on the amount of injected protein. Even the lowest
injected amount of protein (15 mg) gave the maximal respond. As
determined in ELISA, after 4 boost injections the antibody titer of the
sera with the strongest response was 1/50,000. Wild-type animals, in
comparison to BChE 2/2 mice, responded negligibly to the
recombinant BChE and thus were omitted from the study after the
first priming injection. One of the BChE 2/2 mice was used to
generate monoclonal antibodies. Out of one thousand hybridomas
screened, 33 were positive with recombinant human BChE, and after
two further subcultures one IgG1, 11D8, was finally selected. As
illustrated in figure 2a and supplementary data (figure S1), 11D8
detected human BChE in ELISA. Within 1 min, 0.25 ng of
recombinant protein and 4 nl of human plasma are detected while
sensitivity of the detection increases with time; ie. within 1 hour
(figure 2a), 0.2 nl of serum and 0.42 pg of rBChE are detected. 11D8
shifted BChE oligomers in sucrose gradient (figure 2b). 11D8 binds
fixed human BChE in transfected mammalian cells (figure 2c) and
human tissue sections (figure 2d). 11D8 also recognizes purified
recombinant and wild-type human BChE in Western blots (figure 2e).
Presumably the epitope does not contain glycans because deglyco-
sylated protein in situ is still detected in WB (figure 2e). In addition,
the epitope is still present when the different glycosylation sites are
deleted from the complete protein (table 1). It is possible, therefore,
that the immunization was efficient due to a combination of lowered
glycosylation of the recombinant BChE used as an antigen and/or of
the use of the BChE knockout strain as host.
Immunization with BChE purified from human serum
To distinguish between these two possibilities, we immunized the
BChE knockout strain with wild-type human BChE purified from
serum [11]. Mice were immunized in 2 different conditions - with
native or denatured/reduced BChE. Similar to the results with
recombinant BChE, the immune response to purified human BChE
was strong, and detected even after the BChE priming injection. As
expected, serum from mice immunized with denatured BChE gave
stronger and more selective signal by Western blot (figure 3A) than
serum immunized with native enzyme. Sera recognized with
different intensity as little as 0.2 mlo fh u m a np l a s m aa n d8n go f
purified protein. On the other hand, as shown in figure 3B with
staining of BChE expressed in a cell line, sera from mice immunized
with native BChE better recognized the native enzyme. Interestingly
sera from all mice immunized with human BChE cross-reacted with
mouse BChE in Western blots (figure 4B) and one serum from
immunization with native human BChE, labeled mouse BChE
expressed in COS cells (figure 3B). We can conclude, therefore, that
anti-BChE antibody production is as efficient regardless of whether
the BChE immunogen is glycosylated or not, and that using a mouse
that is genetically null for BChE as the target host facilitates
previously unobtainable results of anti-BChE antibody production.
Figure 1. Different steps in the generation of antibodies:
Strategy of immunization. Two high throughput methods ‘‘Knock-
out Mouse Project’’ and ‘‘Protein Structure Initiative’’ are crossed to
generate antibodies: immunization of knockout mice with high quality
protein domains. Each immunized mouse offers a new collection of
antibodies that are used as polyclonal source or that are cloned as
monoclonal source after fusion.
doi:10.1371/journal.pone.0012892.g001
Immunization of Knockouts
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To evaluate the feasibility of generating an antibody against
autologous BChE, we immunized mouse BChE knockouts with
mouse BChE protein. Similar to results with immunization of
these mice with human BChE, a strong immune response to the
antigen was generated and the resultant serum recognized the
protein in all assays (figure 4). The antibody titer in the selected
mouse sera was more than 1/50,000. Out of 1000 hybridoma, 42
were positive with mouse serum and after two further subcultures
three IgG1 were selected, while 4H1 gave the strongest signal. As
illustrated in figure 5A, 4H1 detected recombinant mouse BChE
and BChE in mouse serum in ELISA. 4H1 shifted BChE
oligomers but not AChE oligomers in sucrose gradient
(figure 5B). 4H1 binds fixed mouse BChE in transfected
mammalian cells (figure 2C) and rat tissue sections (figure 2D).
Of note then is that this strategy for antibody generation is not
limited to immunization with the orthologous protein, but is
efficient even when an autologous protein is used.
Discussion
Our results show that immunization of knock-out mouse is very
efficient method for the generation of both polyclonal and monoclonal
antibodies, while both recombinant and natural protein suit the task
and antigen preparation determines the characteristic of the resulting
antibody. The autologous immunization of knock-out strains of mice
Figure 2. Human BChE is recognized by monoclonal antibody 11D8. (A) Selectivity of 11D8 for recombinant and wild-type BChE by ELISA
(60 min detection). (B) 11D8 shifts BChE in sucrose gradient. Sucrose gradient of human PRiMA-BChE complex extracted from COS cells. Binding of
11D8 shifts the peaks of tetramer and dimmer. Wider high-S peak suggests a mixed population of IgG/one tetramer and IgG/two tetramers. (C) 11D8
recognizes BChE expressed by COS cells, anchored by ColQ and PRiMA as documented by confocal microscopy. (D) Immunohistochemistry of human
neuromuscular junction (NMJ). Top, nicotinic acetylcholine receptors are visualized with bungarotoxin (Bung). Bottom, staining with 11D8 labels
BChE. (E) Western blot of human recombinant (r) and wild-type (wt) BChE, (*) after deglycosylation.
doi:10.1371/journal.pone.0012892.g002
Immunization of Knockouts
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this strategy monoclonal antibodies against the prion protein (the
infective agent of scrapie) was possible [12]. This method was also
successfully used to make a monoclonal antibody against apolipopro-
teins [13], while another group claimed successful generation of
polyclonal but failed in generation of monoclonal antibody against
cytokines [14]. We have also successfully used the described strategy to
obtain an antibody against another related protein – mouse
acetylcholinesterase (data not shown). At present we see no reason
why this strategy should not be employed for any protein antigen for
which there is need for an antibody, and are purified protein and a
cognate knockout mouse strain available. First of all, the number of
mutant mice generated over the past 10 years or so has increased
dramatically, so much so that several high throughput methods are in
progress that will generate a null allele for every single gene (http://
www.knockoutmouse.org/ and http://www.eucomm.org/). Impor-
tantly, many of these mutants are viable and live with no apparent
defect in the phenotype until adulthood. Secondly, large amounts of
high quality antigens are available, either from individual studies that
produced full/partial recombinant proteins for 3D structure analysis,
or from an NIH sponsored initiative underway (http://kb.psi-
structuralgenomics.org/about/psi.html) to produce and determine
the structure of all major classes of known proteins.
Despite the satisfying results that we have obtained, we would
like to point out that the proposed strategy does share some of the
limitations of conventional strategies. As with any immunization
based strategy, immunoreactivity towards the introduced protein is
key but sometimes, for still unexplained reasons, this does not
easily occur. Likewise, amounts of the immunizing protein to be
used as an antigen need to be available. Moreover, antibodies that
are produced may have limited use in recognition of the wild-type
protein. The immune response, however, can be different between
individual mice making it possible to select the mouse that
produces antibodies with favorable properties. Lastly, the antibody
could be produced against an epitope that is conserved between
species and thus will be cross reactive.
In some selective cases the properties of knockout mouse
themselves could be a limiting factor, i.e. because of an impaired
immune system or in the case of a partial deletion of the coding
sequence, either alternative promoter or splice variants may produce
a truncated form of the protein rendering the animal tolerant toward
the immunogen. Overall though we feel that the strategy presented,
of using knockout mice to produce antibodies against autologous
antigens, is a promising method that should be more seriously
considered for ‘‘problem’’ antigens, especially in the current climate
of new knockout strains emerging seemingly everyday.
Materials and Methods
Animals
BChE heterozygous mice [9] were maintained in a mixed
background strain 129S1/SvImJ and B6D2. By unsystematic
Table 1. ELISA of extracts from COS cells expressing different mutants of BChE with lowered glycosylation.
h BChE Glycosylation sites activity ELISA
position 17 57 106 241 256 341 455 481 485 486 O.D. O.D.
4 sugar off x x x x x x 0.6260.01 1.7960.03
3 sugar off x x x x x x 1.6360.01 3.0260.07
5 sugar off x x x x x 1.6360.11 2.9960.11
7 sugar off x x x 0.0660.00 0.1460.02
6 sugar off x x x x 0.4860.01 1.3360.03
no DNA 0.0360.00 0.0660.00
human serum x x x x x x x x x out of range out of range
‘‘no DNA’’ is a COS cell extract of non-transfected cells; 100 ml of rat serum was used as a negative control; 8 ml of human serum was used as a positive control.
doi:10.1371/journal.pone.0012892.t001
Figure 3. Mouse polyclonal anti-human BChE antibody raised
against wild-type protein recognizes human and mouse BChE.
(A) Western blot with sera from mice immunized with denatured/
reduced protein (h1–h3) or with native protein (h4–h6). (B) Immuno-
histochemical staining of BChE expressed in COS cells with sera from
mice immunized with the native protein (h4–h6); note that h6
recognizes human and mouse BChE. Human sera, 2 ml (first lane)
and 0.2 ml (second lane) were loaded on gel; (?) unknown protein;
(*) purified wild-type BChE (8 ng).
doi:10.1371/journal.pone.0012892.g003
Immunization of Knockouts
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ground strain was managed in order to avoid random mutations.
Homozygous BChE 2/2 were selected by PCR from crude tissue
extracts after alkaline hydrolysis using a mix of allele specific + and
2 primers (supplementary table S1) and HotStart TaqDNA
polymerase (Qiagen), with an annealing temperature of 65uC.
Mice were maintained under standard conditions at a constant
temperature of 22uC with a 12 - hour daylight cycle. Food and
water were provided ad libitum. In accordance with French
legislation, the investigators had valid licenses to perform
experiments on live vertebrates delivered by the Direction des
Services Ve ´te ´rinaires (Pre ´fecture de Police, Paris, France). The
animal house and the experimental room had received the
agreement of the same authority.
Immunization
Young (25–40 days old) and old (around 95 days) BChE 2/2
mice were immunized with 15–50 mg of antigen in Freund’s
adjuvants (Pierce; # 77140 and #77145) by subcutaneous
injection. Mice were bled from femoral vein 5 days after each
injection and presence of the antibody in the plasma was tested in
ELISA (see below). Once plateau of antibody production was
detected, hybridoma fusion was performed (figure 1). Antibody
titer was determined by ELISA. As a negative control, four wild-
type BChE mice of the same strain and of the same age were
immunized under same condition as BChE 2/2 mice.
Monoclonal antibody generation and screening
Monoclonal antibodies were generated commercially (P.A.R.I.S
Production d’Anticorps & Services, Compie `gne, France) by
hybridoma fusion (SP2/0) followed by 2 subcloning steps.
Hybridomas obtained during preparation were screened for
antibody production by modified ELISA method and then by
Western blot, immunohistochemistry, by ELISA with human,
mouse, rat and cat plasma and mouse tissue extracts (liver, lungs,
muscle).
Isotyping
Isotyping was performed commercially (P.A.R.I.S Production
d’Anticorps & Services, Compie `gne, France) using an RD Biotech
kit. Samples were diluted 1:10 and color development time was
10 min (sample 11D8; 4H1).
ELISA
96-well plate Nunc-Immuno F96 Maxi-Sorp plates (Nunc
GmbH & Co) were coated with 1 mg of native or denatured
recombinant human or mouse BChE per well. Protein was
denatured by 20 min incubation at 99uC, in the presence of 1%
SDS and 35 mM beta-mercaptoethanol. Plates were blocked with
3% non-fat milk and incubated for 2 hours with 1:50 and 1:100
dilution of plasma from immunized animals or with culture
medium from hybridoma cells. Secondary anti-mouse antibody
coupled to horse radish peroxidase (HRP) (Amersham Biosciences
- GE Healthcare Europe GmbH; # NA931) were used in dilution
1:2000 in phosphate-buffered saline (PBS). HRP was revealed with
substrate o-phenylenediamine dihydrochloride (Sigma-Aldrich
Chimie; # P5412).
Modified ELISA
Immunoplates Maxi-Sorp (see above) were coated with 1 mg per
well of affinity pure goat anti-mouse IgG +IgM (Jackson
Immunoresearch laboratories, # 115-005-004) or goat anti-mouse
IgG (P.A.R.I.S Production d’Anticorps & Services, Compie `gne,
France) diluted into 100 ml with PBS. Plates were blocked with
Figure 4. Antibodies from BChE knockout mice immunized with mouse BChE. (A) Confocal microscopy of COS cells expressing mouse
BChE. (B) Western blot of recombinant mouse BChE with sera from mice immunized with recombinant mouse BChE (m1–m3), or from mice
immunized with BChE purified from human serum (h1–h6), or with monoclonal antibody produced against human low-glycosylated BChE (11D8). In
this experiment, each antibody sample was tested with 75 ng, 38 ng and 8 ng of recombinant mouse BChE loaded onto a denaturing gel. In the
11D8 lane, the band marked with ‘‘*’’ represents 750 ng of protein.
doi:10.1371/journal.pone.0012892.g004
Immunization of Knockouts
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in plate, together with or followed by BChE sample. Recombinant
human BChE, human plasma, mouse plasma, rat plasma, cat
plasma, mouse tissue extracts (liver, lungs, muscle) were used in the
assay. Amount of BChE to be used was determined from titration
experiments with recombinant human BChE as discussed in
supplementary figure S1. Signal was revealed as BChE activity
measured with 1 mM butyrylthiocholine, in the presence of 5 mM
5,59-dithiobis-(2-nitrobenzoic acid) (Ellman’s reagent) and 5 mM
Hepes buffer, pH 8.0 for the time period up to 20 hours.
Sensitivity of the antibody was set to the dilution that gave 40%
higher signal comparing to the background.
Transfection of COS cells
DNA of human BChE in pCR/CMV expression vector was a
gift from Dr. David Lenz. Full length human BChE with mutation
of four glycosylation sites Asn17, Asn455, Asn481 and Asn486 was
in expression vector pGS [10] and DNA of mouse BChE in pGS
expression vector were a gift of Oksana Lockridge. rat ColQ [15]
and PRiMA [16] were in pCDNA3. ColQ and PRiMA are a
specific collagen and a small transmembrane protein that organize
BChE in tetramers and anchor them in the extracellular matrix
(ColQ) [15] or in the plasma membrane (PRiMA) [16]. To address
BChE to the cells surface, COS cells were co-transfected with
DNAs of BChE and ColQ or PRiMA. ExGene 500 (Euromedex;
# ET0250) was used for transfection. Cells were grown on poly-
lysine coated glass slides.
Immunohistochemistry of transfected COS cells
BChE was detected at the light microscopic level by immunoflu-
orescence. In brief, cells on glass slides were fixed in 2%
paraformaldehyde in PBS, washed, incubated in 0.1% BSA for
30 min and then in different dilutions of serum fromimmunized mice
or in different dilutions of culture medium from cells producing anti-
BChE antibody with 0.1% BSA for 15 hours at room temperature.
After a second wash, slides were incubated with cyanine 3-conjugated
donkey anti-mouse. After washing, the cells were mounted in
Vectashield mounting medium (Vector Laboratories, Burlingame,
CA; H-1000) and examined in a confocal microscope.
Western Blot
Denatured and reduced purified human BChE were run on
NuPAGE Novex 10% Bis-Tris gel (Invitrogen; # NP0303BOX).
Figure 5. Rodent BChE is recognized by monoclonal antibody 4H1. (A) Selectivity of 4H1 for recombinant and wild-type mouse BChE by
ELISA (60 min detection). (B) 4H1 shifts mouse BChE in sucrose gradient. Sucrose gradient of mouse serum. Binding of 4H1 shifts the peaks of
tetramer. Wider high-S peak suggests a mixed population of IgG/one tetramer and IgG/two tetramers. (C) 4H1 recognizes mouse BChE expressed by
COS cells, anchored PRiMA as documented by confocal microscopy. (D) Immunohistochemistry of young rat neuromuscular junction (NMJ). Right,
nicotinic acetylcholine receptors are visualized with bungarotoxin (Bung). Left, 4H1 labels rat BChE.
doi:10.1371/journal.pone.0012892.g005
Immunization of Knockouts
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per well) were run on NuPAGE Novex 4–12% Bis-Tris gel
(Invitrogen, # NP0323BOX). Monomer of BChE runs close to
albumin on PAGE and the thick band of albumin in plasma
resulting from its high quantity blocks interaction of antibody with
BChE. Using denaturing but non-reducing conditions overcomes
this problem and allows good separation of albumin and BChE
(which remains in dimers). Protein was transferred to PVDF
membrane by iBlot Dry Blotting system (Invitrogen, # IB4010)
and protein transferred was confirmed by visualization with
Ponceau. Membrane was then blocked with 5% non-fat milk and
incubated with anti-BChE antibody containing sample. Secondary
anti-mouse antibody coupled to HRP (Amersham Biosciences -
GE Healthcare Europe GmbH; # NA931) were used in dilution
1:10000 in PBS. ECL Western Blotting detection reagent
(Amersham Biosciences - GE Healthcare Europe GmbH, #
RPN2106) was used to detected the signal.
Sucrose gradient
Transfected cells were extracted in 25 mM Tris-HCl pH 7.4,
0.8 M NaCl, 10 mM EDTA, 1% CHAPS and protease inhibitors
2 mM benzamidine and mouse serum was diluted by 2 in the
same buffer. The extracts were incubated with 1 mg of mABs on
ice for few hours. Sedimentation analyses of BChE molecular
forms were performed in 5–20% (wt/vol) sucrose gradients
containing the same buffer except CHAPS was replaced by
0.2% Brij-97 (polyoxyethylene 10 oleoyl ether, SIGMA Aldrich),
to shift amphiphilic oligomers. The gradients were centrifuged at
38,000 rpm at 7uC for 18.5 h, using a SW41 rotor (Beckman
Instruments). Each gradient was collected in 48 fractions and
assayed for BChE activity. Fractions were calibrated with internal
sedimentation markers (alkaline phosphatase (6.1S) and ß-
galactosidase (16S)). Sedimentation marker profiles were used to
establish a linear relation between fraction numbers and Svedberg
units.
Supporting Information
Figure S1 Titration of 11D8 by ELISA. 11D8 was titrated in a
plate coated with secondary antibody (1 mg/well). Based on the
preliminary studies with polyclonal anti-hBChE antibody (inter-
mediate product), 0.1 mg of rhBChE (70 mU) was used for
titration. Amount of bound BChE was determined by an activity
assay with butyrylthiocholine (1 mM) in the presence of DTNB.
Hydrolysis was followed over a period of up to 4 hours, at variable
intervals. Figure represents results obtained after 15 min of
development.
Found at: doi:10.1371/journal.pone.0012892.s001 (0.17 MB TIF)
Table S1 Primers designed for genotyping of heterozygous and
homozygous BChE mutant mice.
Found at: doi:10.1371/journal.pone.0012892.s002 (0.03 MB
DOC)
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